About polycythemia vera (PV)

Living with PV

Living with PV may mean ongoing challenges with hematocrit (HCT) control and symptoms, like fatigue

Polycythemia vera (polly-sy-THEE-me-uh VEER-uh) or PV, is a rare, chronic blood cancer that affects about 90,000 people in the United States. In PV, the body makes too many red blood cells, a condition known as erythrocytosis. When this happens, the blood can become thicker than normal.

For some people, living with PV may mean ongoing challenges with keeping HCT controlled and managing symptoms, like fatigue, that can affect daily life.

HCT below 45%

Keeping HCT below 45% matters

Hematocrit, or HCT, is the percentage of red blood cells in your blood. In PV, too many red blood cells can cause HCT to rise.
When your HCT remains too high (45% or above) it can make your blood thicker, and it may not flow as easily. This can increase the risk of serious complications, such as: blood clots, heart problems, and strokes.

Infographic showing HCT at 45%–50% associated with approximately 4x higher risk of serious blood-clot related events or death from from heart-related problems compared to those with HCT levels below 45%

Symptoms

Symptoms can still affect day-to-day life

Symptoms of PV, like fatigue, and the burden of keeping HCT under control (below 45%) can cause a strain on your mental and physical well-being.

To control your HCT, you may need ongoing monitoring and management, including frequent and sometimes disruptive rescue phlebotomies.

The frequency and duration of appointments can affect your mood, sleep, work, and relationships.

You may experience ongoing fatigue related to your PV that can affect your day-to-day life

Infographic showing ~2 in 3 people with PV report emotional pressure; ~8 in 10 say PV symptoms affect daily life and lead to isolation

All individuals in images are actor portrayals.

IMPORTANT SAFETY INFORMATION

Before using MIMRYLO, tell your healthcare provider about all of your medical conditions, including if you:

are pregnant or plan to become pregnant. MIMRYLO may harm your unborn baby.
Females who are able to become pregnant:

Your healthcare provider may do a pregnancy test before you start treatment with MIMRYLO.
Use effective birth control (contraception) during treatment and for at least 30 days after the final dose of MIMRYLO.
Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with MIMRYLO.
Stop taking MIMRYLO if you become pregnant.

are breastfeeding or plan to breastfeed. It is not known if MIMRYLO passes into your breast milk. Do not breastfeed during treatment with MIMRYLO and for 30 days after the final dose of MIMRYLO. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of MIMRYLO?

MIMRYLO may cause serious side effects, including:

New or worsening increased blood platelets (thrombocytosis). MIMRYLO may increase blood platelet counts. Your healthcare provider will do blood tests when you start and during treatment with MIMRYLO to check your platelet counts.

Injection site reactions. MIMRYLO may cause injection-site reactions such as redness, itching, pain, swelling, bruising, hardening at the injection site, and irritation. If you get an injection site reaction, apply ice packs, steroid cream, or take medicines as needed to treat injection site pain and swelling.

Your healthcare provider may change your dose or stop treatment with MIMRYLO if you have side effects.

The most common side effects of MIMRYLO are:

injection site reactions

low red blood cell count (anemia)

These are not all of the possible side effects of MIMRYLO. Call your doctor for medical advice about side effects. You may report side effects to Takeda at 1-844-662-8532 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.